Condition: HTLV-1 Infection · HTLV I Associated Myelopathies · HTLV I Associated T Cell Leukemia Lymphoma · Sponsor: Carlos Brites
This phase 2b, open-label, randomized controlled trial evaluates the efficacy and safety of dolutegravir (DTG) alone versus dolutegravir combined with tenofovir disoproxil fumarate (TDF) in individuals with HTLV-1 infection and associated clinical manifestations. The primary objective is to compare changes in HTLV-1 proviral load at 24 and 48 weeks. Secondary outcomes include clinical, functional, immunological, and quality-of-life measures.
This description comes directly from the study's public registry record.
Carlos Brites, MD, PhD · +5571992329552 · crbrites@gmail.com
Estela Luz · +5571999867515 · eluz5@yahoo.com.br
Always discuss trial participation with your own doctor first.
| Hospital Universitário Professor Edgard Santos | Salvador, Estado de Bahia, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07555431